SLFN11 and small cell lung carcinoma: Interestingly, biomarkers may help to select SCLC patients with a higher chance of efficacy of lurbinectedin: preclinical studies showed that a low SLFN11 expression is predicting relative resistance to lurbinectedin, with potential induction of synthetic lethality with ATR inhibitors.11